Login

I cannot remember my username

Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

Important: Flash Alert

By Paul MampillyPosted December 2, 2014

One of our Ebola companies is now below our 45% stop loss point. All my research and sources tell me that this company’s Ebola medication is likely to be approved and used when Ebola becomes widespread. I still believe that a bigger, wider Ebola outbreak lies ahead. Because of the huge potential gains when that happens, I am going to retain this company in our portfolio…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Paul Mampilly

Back when Paul Mampilly was growing up in India, nobody talked about the stock market. Yet as a kid, Paul read voraciously about the Great Crash of 1929 and found it fascinating.

When he turned 18, he came to the United States by himself. Since then, he’s had close to 25 years of investment...

View More By Paul Mampilly

Related Posts

FLASH BUY: Your Exclusive PDUFA Booster Shot

By Paul MampillyPosted March 26, 2014

Yesterday, you received your first view of our new FDA Trader service. Importantly, we outlined four special categories that make up our portfolio. Today, your exclusive recommendation falls into that first category: PDUFA booster shots.

Important: Flash Alert

By Paul MampillyPosted December 19, 2014

One of our cancer stocks is down 45% this morning because its drug did not show superior results in a clinical trial for breast cancer run by their business partner Roche. While this result is disappointing, it does not change the fact that the drug is going to be a multi-billion blockbuster. This result does also does not change the sales or profits that the drug is going to generate for this year or 2015...

Take 60% Gains on This Pharmaceutical Buyout

By Paul MampillyPosted January 12, 2015

If you followed our recommendation to buy this PDUFA company in August 2014, you've made 60% in less than six months. Congratulations! You're a rock star! Now it's time to ring the register and take our profits.